SCHEMBL6407136

SCHEMBL6407136

CN(C)c1ccc(CNC(=O)[C@@H](Cc2ccccc2)NC(=O)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.64
MMP8 P22894 2/20 0.54
ANPEP P15144 1/20 0.53
ALDH1A1 P00352 1/20 0.53
KMT2A Q03164 1/20 0.53
MMP1 P03956 6/20 0.53
FCER2 P06734 5/20 0.53
MMP9 P14780 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KLKB1 P03952 1/20 0.49
CTSS P25774 1/20 0.49
CTSK P43235 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA3 P07451 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA5A P35218 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160205 0.87 F7 (0.59) F7MMP8ANPEPALDH1A1KMT2A
SCHEMBL6411176 0.85 F7 (0.57) F7MMP8ALDH1A1KMT2AMMP1
SCHEMBL6407898 0.83 F7 (0.55) F7MMP8ANPEPALDH1A1KMT2A
SCHEMBL6410493 0.83 MMP1 (0.57) F7ALDH1A1KMT2AMMP1
SCHEMBL5158191 0.82 F7 (0.55) F7MMP8ALDH1A1KMT2A
SCHEMBL5158199 0.82 F7 (0.55) F7MMP8ALDH1A1KMT2A
SCHEMBL6407102 0.80 F7 (0.52) F7MMP8ANPEPALDH1A1KMT2A
SCHEMBL4418014 0.79 F7 (1.00) F7ANPEPMMP1KLKB1
SCHEMBL6409719 0.79 F7 (0.51) F7ANPEPALDH1A1KMT2AMMP1
SCHEMBL23529664 0.79 CTSS (0.64) MMP8KMT2AATMCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050277690-A1 Small molecules for treatment of hypercholesterolemia and related diseases AVANIR PHARMACEUTICALS 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277690-A1 Small molecules for treatment of hypercholesterolemia and related diseases LDLR, NPC1L1, CETP F7 4389/4885MMP8 3190/4885ANPEP 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.